HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Ait-Khaled, Mounir
HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. [electronic resource] - Antiviral therapy Apr 2003 - 111-20 p. digital
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
1359-6535
Alkynes
Anti-HIV Agents--therapeutic use
Antiretroviral Therapy, Highly Active
Benzoxazines
Carbamates
Cohort Studies
Cyclopropanes
Dideoxynucleosides--therapeutic use
Drug Resistance, Viral--genetics
Drug Therapy, Combination
Furans
Genotype
HIV Infections--drug therapy
HIV Protease--genetics
HIV Reverse Transcriptase--genetics
HIV-1--drug effects
Humans
Mutation
Oxazines--therapeutic use
Salvage Therapy
Sulfonamides--therapeutic use
HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. [electronic resource] - Antiviral therapy Apr 2003 - 111-20 p. digital
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
1359-6535
Alkynes
Anti-HIV Agents--therapeutic use
Antiretroviral Therapy, Highly Active
Benzoxazines
Carbamates
Cohort Studies
Cyclopropanes
Dideoxynucleosides--therapeutic use
Drug Resistance, Viral--genetics
Drug Therapy, Combination
Furans
Genotype
HIV Infections--drug therapy
HIV Protease--genetics
HIV Reverse Transcriptase--genetics
HIV-1--drug effects
Humans
Mutation
Oxazines--therapeutic use
Salvage Therapy
Sulfonamides--therapeutic use